Dr Reddy`s Miryalaguda facility gets 3 USFDA observations


Dr Reddy's Laboratories said the US health regulator has made three observations after completing inspection of its Miryalaguda facility. "The audit of the company's Active Pharmaceutical Ingredients (API) manufacturing plant at Miryalaguda, by the United States Food and Drug Administration (USFDA), has been completed on February 21, 2017," Dr Reddy's Laboratories said in a filing to BSE.

Comments

Popular posts from this blog

Daily equity Market By Ripplesadvisory Report 16-Aug-2016

Axis Bank agrees to buy to payments wallet provider FreeCharge for $60 million

Axis Bank Declines after Reporting Tepid Q4 Results